贝派地酸与他汀不耐受患者的心血管结局
该双盲随机安慰剂对照试验纳入因不可接受的不良反应而不能或不愿服用他汀、且已患或高危心血管病的患者13970例,随机接受口服贝派地酸180 mg每日一次或安慰剂。中位随访40.6个月,贝派地酸组主要终点事件(心血管死亡、非致死性心肌梗死、非致死性卒中或冠状动脉血运重建)发生率为11.7%,安慰剂组为13.3%(HR 0.87,95%CI 0.79–0.96,P=0.004)。贝派地酸还降低了心血管死亡/非致死性卒中/非致死性心肌梗死复合终点、致死性或非致死性心肌梗死及冠状动脉血运重建的发生率。痛风、胆石症及血清肌酐、尿酸、肝酶轻度升高的发生率在贝派地酸组更高。
要点
- 他汀不耐受且已患或高危心血管病患者,贝派地酸180 mg每日一次口服使主要不良心血管事件发生率11.7% vs 安慰剂13.3%(HR 0.87,95%CI 0.79–0.96,P=0.004)。
- 贝派地酸降低致死性或非致死性心肌梗死发生率3.7% vs 4.8%(HR 0.77,95%CI 0.66–0.91,P=0.002)及冠状动脉血运重建6.2% vs 7.6%(HR 0.81,95%CI 0.72–0.92,P=0.001)。
- 贝派地酸对致死性或非致死性卒中、心血管死亡及全因死亡无显著影响。
- 贝派地酸组痛风(3.1% vs 2.1%)和胆石症(2.2% vs 1.2%)发生率更高,血清肌酐、尿酸及肝酶轻度升高的发生率也更高。
- 基线平均LDL胆固醇两组均为139.0 mg/dL,6个月时贝派地酸较安慰剂多降低29.2 mg/dL,降幅百分比差异为21.1个百分点(有利于贝派地酸)。
适用人群与场景
- 因不可接受的不良反应而不能或不愿服用他汀(「他汀不耐受」)且已患或高危心血管病的患者。
处置流程与药物剂量
- 贝派地酸180 mg每日一次口服,安慰剂对照。
研究设计与关键结果
- 双盲、随机、安慰剂对照试验,共13970例患者随机分组,贝派地酸组6992例,安慰剂组6978例,中位随访40.6个月。
- 主要终点(心血管死亡、非致死性心肌梗死、非致死性卒中或冠状动脉血运重建四组分复合终点)发生率贝派地酸组11.7%(819例)vs 安慰剂组13.3%(927例),HR 0.87,95%CI 0.79–0.96,P=0.004。
- 心血管死亡、非致死性卒中或非致死性心肌梗死复合终点发生率贝派地酸组8.2%(575例)vs 安慰剂组9.5%(663例),HR 0.85,95%CI 0.76–0.96,P=0.006。
- 致死性或非致死性心肌梗死发生率贝派地酸组3.7%(261例)vs 安慰剂组4.8%(334例),HR 0.77,95%CI 0.66–0.91,P=0.002。
- 冠状动脉血运重建发生率贝派地酸组6.2%(435例)vs 安慰剂组7.6%(529例),HR 0.81,95%CI 0.72–0.92,P=0.001。
- 贝派地酸对致死性或非致死性卒中、心血管死亡及全因死亡无显著影响。
- 痛风发生率贝派地酸组3.1% vs 安慰剂组2.1%,胆石症发生率贝派地酸组2.2% vs 安慰剂组1.2%,血清肌酐、尿酸及肝酶轻度升高的发生率在贝派地酸组更高。
- 基线平均LDL胆固醇两组均为139.0 mg/dL,6个月时贝派地酸较安慰剂多降低29.2 mg/dL,降幅百分比差异为21.1个百分点(有利于贝派地酸)。
证据类型、等级与局限
- 证据类型:双盲、随机、安慰剂对照试验(CLEAR Outcomes,NCT02993406)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于他汀不耐受且已患或高危心血管病的患者,贝派地酸180 mg每日一次口服与主要不良心血管事件风险降低相关。
- 使用贝派地酸时需注意痛风、胆石症及血清肌酐、尿酸、肝酶轻度升高的发生率高于安慰剂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain.
METHODS: We conducted a double-blind, randomized, placebo-controlled trial involving patients who were unable or unwilling to take statins owing to unacceptable adverse effects ("statin-intolerant" patients) and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. The primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization.
RESULTS: A total of 13,970 patients underwent randomization; 6992 were assigned to the bempedoic acid group and 6978 to the placebo group. The median duration of follow-up was 40.6 months. The mean LDL cholesterol level at baseline was 139.0 mg per deciliter in both groups, and after 6 months, the reduction in the level was greater with bempedoic acid than with placebo by 29.2 mg per deciliter; the observed difference in the percent reductions was 21.1 percentage points in favor of bempedoic acid. The incidence of a primary end-point event was significantly lower with bempedoic acid than with placebo (819 patients [11.7%] vs. 927 [13.3%]; hazard ratio, 0.87; 95% confidence interval [CI], 0.79 to 0.96; P = 0.004), as were the incidences of a composite of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (575 [8.2%] vs. 663 [9.5%]; hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P = 0.006); fatal or nonfatal myocardial infarction (261 [3.7%] vs. 334 [4.8%]; hazard ratio, 0.77; 95% CI, 0.66 to 0.91; P = 0.002); and coronary revascularization (435 [6.2%] vs. 529 [7.6%]; hazard ratio, 0.81; 95% CI, 0.72 to 0.92; P = 0.001). Bempedoic acid had no significant effects on fatal or nonfatal stroke, death from cardiovascular causes, and death from any cause. The incidences of gout and cholelithiasis were higher with bempedoic acid than with placebo (3.1% vs. 2.1% and 2.2% vs. 1.2%, respectively), as were the incidences of small increases in serum creatinine, uric acid, and hepatic-enzyme levels.
CONCLUSIONS: Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization). (Funded by Esperion Therapeutics; CLEAR Outcomes ClinicalTrials.gov number, NCT02993406.).
参考来源
- Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023. PMID: 36876740. doi:10.1056/NEJMoa2215024
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。